Miricorilant

Generic Name: Miricorilant

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃F_₃N_₂O_₂

CAS Number: 1400902-13-7

Unique Ingredient Identifier: 311Y5GV21M

Background: Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results

Corcept Therapeutics reports Q3 2024 revenue of $182.5M, up 48% YoY, and increases 2024 revenue guidance to $675-$700M. Net income per share is $0.41 (diluted), with cash and investments at $547.6M. The company plans to submit an NDA for relacorilant this quarter, supported by Phase 3 GRADIENT trial results.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy